Final Lock News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Final Lock. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Final Lock Today - Breaking & Trending Today

Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus

Published: May 31, 2023

- At week 24, upadacitinib 30 mg given alone or as a combination therapy (ABBV-599 high dose [elsubrutinib 60 mg and upadacitinib 30 mg]) met the primary...

Source: prnewswire.com

Related Topics:

United StatesJoan MerrillRoopal ThakkarUpadacitinib MonotherapyArthritis Clinical Immunology Research ProgramCenters For DiseaseEuropean CongressLupus Erythematosus National AssessmentExchange CommissionOklahoma Medical Research FoundationAbbvie Deutschland Gmbh CoBritish Isles Lupus Assessment GroupResponder IndexLupus Low Disease Activity StateFlare IndexClinical Immunology ResearchAllergan AestheticsPrivate Securities Litigation Reform ActQuarterly ReportsFinal LockKey ResultsIntended IndicationSystemic Lupus ErythematosusAdult Systemic Lupus ErythematosusDisease Activity